Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Joensuu H, et al. Among authors: leinonen h, leinonen m. J Clin Oncol. 2009 Dec 1;27(34):5685-92. doi: 10.1200/JCO.2008.21.4577. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884557 Clinical Trial.
Risk for subsequent coronary artery disease after preeclampsia.
Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Haukkamaa L, et al. Among authors: leinonen h. Am J Cardiol. 2004 Mar 15;93(6):805-8. doi: 10.1016/j.amjcard.2003.11.065. Am J Cardiol. 2004. PMID: 15019902
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing.
Luostarinen A, Kailaanmäki A, Turkki V, Köylijärvi M, Käyhty P, Leinonen H, Albers-Skirdenko V, Lipponen E, Ylä-Herttuala S, Kaartinen T, Lesch HP, Kekarainen T. Luostarinen A, et al. Among authors: leinonen h. Cytotherapy. 2024 Apr 7:S1465-3249(24)00600-5. doi: 10.1016/j.jcyt.2024.04.002. Online ahead of print. Cytotherapy. 2024. PMID: 38661611 Free article.
Metabolic characteristics of transmembrane prolyl 4-hydroxylase (P4H-TM) deficient mice.
Ala-Nisula T, Halmetoja R, Leinonen H, Kurkela M, Lipponen HR, Sakko S, Karpale M, Salo AM, Sissala N, Röning T, Raza GS, Mäkelä KA, Thevenot J, Herzig KH, Serpi R, Myllyharju J, Tanila H, Koivunen P, Dimova EY. Ala-Nisula T, et al. Among authors: leinonen h. Pflugers Arch. 2024 Feb 24. doi: 10.1007/s00424-024-02920-5. Online ahead of print. Pflugers Arch. 2024. PMID: 38396259
Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition.
Luu JC, Saadane A, Leinonen H, Choi EH, Gao F, Lewandowski D, Halabi M, Sander CL, Wu A, Wang JM, Singh R, Gao S, Lessieur EM, Dong Z, Palczewska G, Mullins RF, Peachey NS, Kiser PD, Tabaka M, Kern TS, Palczewski K. Luu JC, et al. Among authors: leinonen h. Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2221045120. doi: 10.1073/pnas.2221045120. Epub 2023 May 1. Proc Natl Acad Sci U S A. 2023. PMID: 37126699 Free PMC article.
Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy.
Eriksson RAE, Nieminen T, Galibert L, Peltola SK, Tikkanen P, Käyhty P, Leinonen HM, Oruetxebarria I, Lepola S, Valkama AJ, Lipponen EM, Lesch HP, Ylä-Herttuala S, Airenne KJ. Eriksson RAE, et al. Among authors: leinonen hm. Front Med (Lausanne). 2023 Mar 3;10:1143748. doi: 10.3389/fmed.2023.1143748. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36936246 Free PMC article.
120 results